Detailed Narrative
Record Q1 Performance and Raised Full-Year Outlook
Natera reported a strong Q1 FY25, achieving $502 million in revenue, a 37% increase year-over-year, and processing a record 855,000 units. This performance was driven by outstanding volume growth across all segments, including a significant sequential step-up in Women's Health and a record quarter for Signatera. Consequently, the company raised its full-year revenue guidance by $70 million at the midpoint, now expecting revenues between $1.94 billion and $2.02 billion, implying approximately 26% growth ex-true-up📎s.
Oncology Pipeline and Data Leadership
The company highlighted its robust oncology pipeline and extensive data generation efforts for Signatera. Upcoming presentations at ESMO Breast and ASCO include data from the ISPY-2 trial in breast cancer, the DARE randomized study, and the largest sarcoma study to date, demonstrating Signatera's utility in various cancer types and settings. These studies, many initiated years ago, reinforce Natera's leadership in MRD and are expected to further expand clinical utility and adoption.
Gross Margin Expansion and ASP Improvement
Natera continued to demonstrate strong gross margin expansion, reaching 63% in Q1, with underlying gross margin improving 110 basis points sequentially to 60.4%. This improvement was attributed to increased average selling prices (ASPs) across Women's Health, Organ Health, and Oncology, alongside scale efficiencies from robust volume growth. The company maintains a long-term goal of achieving gross margins above 70%, driven by further ASP increases from guideline changes and commercial payer reimbursement.
Strategic Investments for Future Growth
Despite generating $23 million in cash flow during the quarter, Natera emphasized its commitment to strategic investments, particularly in Signatera. Recognizing Signatera's potential to generate over $5 billion in annual revenue, the company is funding high-return-on-investment initiatives in commercial operations, clinical trials, and product improvements. This investment strategy aims to maximize out-year revenue growth while maintaining cash flow breakeven for the full year.
Organ Health Advancements with Prospera
In Organ Health, Natera reported strong year-on-year growth exceeding 50%. The company highlighted positive readouts from the prospective DEFINE study in heart transplantation, demonstrating Prospera's ability to predict clinical outcomes and outperform biopsy in predicting graft dysfunction. The study also validated the novel Donor Quantity Score (DQS), which, when combined with donor fraction, delivered improved sensitivity and specificity, including a 37% reduction in false positives.
Colorectal Cancer Screening Progress
Natera provided updates on its colorectal cancer screening initiatives. The PROSEE study has completed enrollment of over 3,000 patients, with results expected by the end of the year. Additionally, the FDA-enabling FIND study is on track to enroll its first patient this month, mirroring the design of PROSEE to ensure reliable data for regulatory submission. These efforts underscore the company's commitment to expanding into the significant colorectal cancer screening market.
Global Expansion and Market Penetration
The company is making progress on global expansion, with the Signatera regulatory submission in Japan currently under review by the PMDA, expected to be approved by late 2025 or early 2026. This would be followed by a reimbursement submission, potentially impacting the top line by late 2026. Domestically, Natera noted that over 45% of oncologists in the U.S. ordered a Signatera test last quarter, indicating broad, albeit early-stage, market penetration.